Published in Acad Med on July 01, 2012
High-reliability health care: getting there from here. Milbank Q (2013) 1.23
A culture of respect. Acad Med (2013) 1.05
Physicians criticizing physicians to patients. J Gen Intern Med (2013) 1.00
Self-reported patient safety competence among new graduates in medicine, nursing and pharmacy. BMJ Qual Saf (2012) 0.99
Integrating patient safety into health professionals' curricula: a qualitative study of medical, nursing and pharmacy faculty perspectives. BMJ Qual Saf (2013) 0.92
Interns' experiences of disruptive behavior in an academic medical center. J Grad Med Educ (2013) 0.91
Direct observation of respectful maternity care in five countries: a cross-sectional study of health facilities in East and Southern Africa. BMC Pregnancy Childbirth (2015) 0.89
Have restricted working hours reduced junior doctors' experience of fatigue? A focus group and telephone interview study. BMJ Open (2014) 0.86
The prevalence of disrespect and abuse during facility-based childbirth in urban Tanzania. BMC Pregnancy Childbirth (2016) 0.84
Interprofessional collaboration between residents and nurses in general internal medicine: a qualitative study on behaviours enhancing teamwork quality. PLoS One (2014) 0.84
Confronting safety gaps across labor and delivery teams. Am J Obstet Gynecol (2013) 0.83
Why medical schools are tolerant of unethical behavior. Ann Fam Med (2015) 0.81
Patient safety in the era of healthcare reform. Clin Orthop Relat Res (2015) 0.79
Applying a participatory approach to the promotion of a culture of respect during childbirth. Reprod Health (2016) 0.78
Tumultuous atmosphere (physical, mental), the main barrier to emergency department inter-professional communication. Glob J Health Sci (2014) 0.78
A first step toward understanding patient safety. Korean J Anesthesiol (2016) 0.78
Mitigating disrespect and abuse during childbirth in Tanzania: an exploratory study of the effects of two facility-based interventions in a large public hospital. Reprod Health (2016) 0.78
Restoring professionalism: the physician fitness-for-duty evaluation. Gen Hosp Psychiatry (2013) 0.77
Altering workplace attitudes for resident education (A.W.A.R.E.): discovering solutions for medical resident bullying through literature review. BMC Med Educ (2016) 0.76
Are surgeons and anesthesiologists lying to each other or gaming the system? A national random sample survey about "truth-telling practices" in the perioperative setting in the United States. Patient Saf Surg (2015) 0.76
Disrespectful Behavior in Health Care: Its Impact, Why It Arises and Persists, And How to Address It-Part 2. P T (2017) 0.75
Physicians' interpersonal relationships and professional standing seen through the eyes of the general public in Croatia. Patient Prefer Adherence (2014) 0.75
Office-based surgical and medical procedures: educational gaps. Ochsner J (2012) 0.75
Describing team development within a novel GP-led urgent care centre model: a qualitative study. BMJ Open (2016) 0.75
In reply to Alexander et al. Acad Med (2013) 0.75
Interprofessional team management in pediatric critical care: some challenges and possible solutions. J Multidiscip Healthc (2016) 0.75
Conflict management: difficult conversations with difficult people. Clin Colon Rectal Surg (2013) 0.75
A model of influences on the clinical learning environment: the case for change at one U.S. medical school. BMC Med Educ (2017) 0.75
Disruptive behaviour in the perioperative setting: a contemporary review. Can J Anaesth (2016) 0.75
A Compelling Call to Action to Establish a Culture of Respect. P T (2015) 0.75
Perceptions of mistreatment among trainees vary at different stages of clinical training. BMC Med Educ (2017) 0.75
Descriptors for unprofessional behaviours of medical students: a systematic review and categorisation. BMC Med Educ (2017) 0.75
Esophageal cancer. N Engl J Med (2003) 15.23
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Systemic therapy for colorectal cancer. N Engl J Med (2005) 8.94
Shared decision making--pinnacle of patient-centered care. N Engl J Med (2012) 8.74
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA (2008) 4.61
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol (2007) 4.32
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol (2005) 3.50
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol (2003) 3.27
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med (2003) 3.01
A compendium of potential biomarkers of pancreatic cancer. PLoS Med (2009) 3.00
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol (2009) 2.94
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA (2007) 2.84
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
A middle ground on public accountability. N Engl J Med (2004) 2.72
Design and implementation of an application and associated services to support interdisciplinary medication reconciliation efforts at an integrated healthcare delivery network. J Am Med Inform Assoc (2006) 2.70
Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA (2008) 2.67
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol (2003) 2.52
Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol (2006) 2.49
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol (2006) 2.48
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought. J Clin Oncol (2012) 2.45
Advancing the science of patient safety. Ann Intern Med (2011) 2.45
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol (2004) 2.30
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res (2003) 2.24
Adjuvant treatment of colorectal cancer. CA Cancer J Clin (2007) 2.22
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol (2007) 2.22
Analysis & commentary. Measuring patient experience as a strategy for improving primary care. Health Aff (Millwood) (2010) 2.20
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer (2003) 2.19
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol (2004) 2.18
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol (2005) 2.17
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol (2005) 2.16
American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology (2006) 2.14
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
Surgery is different: a response to the IOM report. Am J Surg (2009) 2.12
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 2.10
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Perspective: a culture of respect, part 2: creating a culture of respect. Acad Med (2012) 2.06
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol (2006) 1.94
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol (2006) 1.89
The top patient safety strategies that can be encouraged for adoption now. Ann Intern Med (2013) 1.87
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol (2004) 1.86
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol (2012) 1.84
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med (2002) 1.75
APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther (2004) 1.71
Merkel cell carcinoma. J Clin Oncol (2002) 1.71
Cottage industry to postindustrial care--the revolution in health care delivery. N Engl J Med (2010) 1.69
US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol (2009) 1.65
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Case records of The Massachusetts General Hospital: Case 34-2010: a 65-year-old woman with an incorrect operation on the left hand. N Engl J Med (2010) 1.63
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol (2003) 1.62
Evaluating the use of a modified CAHPS survey to support improvements in patient-centred care: lessons from a quality improvement collaborative. Health Expect (2008) 1.60
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Classification and consequences of errors in otolaryngology. Laryngoscope (2004) 1.59
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol (2008) 1.57
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther (2004) 1.57
Saving billions of dollars--and physicians' time--by streamlining billing practices. Health Aff (Millwood) (2010) 1.53
Hepatitis A--the price of progress. N Engl J Med (2005) 1.52
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol (2007) 1.46
Nasal glioma and encephalocele: diagnosis and management. Laryngoscope (2003) 1.46
Massachusetts General Physicians Organization's quality incentive program produces encouraging results. Health Aff (Millwood) (2013) 1.40
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology (2002) 1.40
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst (2002) 1.38
The effects of HMO penetration on preventable hospitalizations. Health Serv Res (2004) 1.38
Perspective: Physician leadership in quality. Acad Med (2009) 1.38
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol (2009) 1.38
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35